FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Pour des fins de recherche uniquement. Déclaration complète →

Bibliothèque de stacks

GH Max Stack

GH Optimizationadvanced

88

synergie

88
Share
Pépétides

3

Moyenne journalière en mcg

25,586

Niveau

advanced

Ajouté

May 17, 2026

Aperçu

The GH Max Stack represents the most aggressive non-exogenous approach to maximizing growth hormone output, combining three distinct mechanisms of GH stimulation. CJC-1295 with DAC (Drug Affinity Complex) is a modified GHRH analog conjugated to a protein that extends its half-life to approximately 8 days. Unlike the no-DAC version, it provides a sustained elevation of baseline GH levels rather than discrete pulses, creating a continuously elevated "floor" of GH secretion throughout the week. MK-677 (Ibutamoren) is an orally active, non-peptide ghrelin receptor agonist with a 24-hour half-life. It provides continuous GHS-R1a activation, complementing the sustained GHRH signaling from CJC-1295 with DAC. Clinical trials have demonstrated MK-677 increases IGF-1 levels by 40-60% in elderly subjects and improves nitrogen balance — a surrogate for anabolic activity. Daily Ipamorelin injections add targeted GH pulses on top of the elevated baseline, creating both sustained elevation and superimposed pulsatile peaks. This triple-mechanism approach produces GH and IGF-1 levels that approach or exceed physiological youth ranges. However, the advanced classification reflects significant considerations: MK-677 substantially increases appetite (via ghrelin pathway activation), may raise fasting blood glucose and HbA1c over time, and can cause water retention. The sustained GH elevation from CJC-1295 with DAC means less receptor recovery time compared to pulsatile protocols. This stack requires regular monitoring of fasting glucose, IGF-1 levels, and ideally HbA1c every 3 months. It is contraindicated in individuals with diabetes, pre-diabetes, active malignancy, or family history of pituitary tumors.

Protocole de dose

CJC-1295 (with DAC)

Once per week· subcutaneous

Lire plus sur CJC-1295 (with DAC) →

2,000 mcg

par dose

Ipamorelin

Every day· subcutaneous

Lire plus sur Ipamorelin →

300 mcg

par dose

MK-677 (Ibutamoren)

Every day· oral

Lire plus sur MK-677 (Ibutamoren) →

25,000 mcg

par dose

Objectifs & Preuves

Maximum GH outputMuscle growthRecoveryIGF-1Body composition
Niveau d'évidence :Essai clinique humain

Avertissements

  • MK-677 increases appetite significantly and may raise blood glucose. Not suitable for diabetics or pre-diabetics. CJC-1295/Ipamorelin remain FDA Category 2 (restricted) as of July 2026.

Comments

Sign in to join the discussion

Avertissement : Ce stack est soumis par la communauté et est destiné à des fins de recherche uniquement. Peptide Contacts ne vérifie pas la sécurité ou l'efficacité des stacks soumis. Consultez toujours un professionnel qualifié de la santé avant d'utiliser tout protocole de péptides.